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Abstract
Background: Globally it is estimated that 480 000 people developed multidrug-resistant tuberculosis (MDR-TB) in
2014 and 190 000 people died from the disease. Successful treatment outcomes are achieved in only 50 % of
patients with MDR-TB, compared to 86 % for drug susceptible disease. It is widely held that delay in time to
initiation of treatment for MDR-TB is an important predictor of treatment outcome. The objective of this review was
to assess the existing evidence on the outcomes of multidrug- and extensively drug-resistant tuberculosis patients
treated early (≤4 weeks) versus late (>4 weeks) after diagnosis of drug resistance.
Methods: Eight sources providing access to 17 globally representative electronic health care databases, indexes,
sources of evidence-based reviews and grey literature were searched using terms incorporating time to treatment
and MDR-TB. Two-stage sifting in duplicate was employed to assess studies against pre-specified inclusion and
exclusion criteria. Only those articles reporting WHO-defined treatment outcomes were considered for inclusion.
Articles reporting on fewer than 10 patients, published before 1990, or without a comparison of outcomes in
patient groups experiencing different delays to treatment initiation were excluded.
Results: The initial search yielded 1978 references, of which 1475 unique references remained after removal of
duplicates and 28 articles published pre-1990. After title and abstract sifting, 64 papers underwent full text review.
None of these articles fulfilled the criteria for inclusion in the review.
Conclusions: Whilst there is an inherent logic in the theory that treatment delay will lead to poorer treatment
outcomes, no published evidence was identified in this systematic review to support this hypothesis. Reports of
programmatic changes leading to reductions in treatment delay exist in the literature, but attribution of differences
in outcomes specifically to treatment delay is confounded by other contemporaneous changes. Further primary
research on this question is not considered a high priority use of limited resources, though where data are available,
improved reporting of outcomes by time to treatment should be encouraged.
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Background
The widespread emergence of multidrug-resistant tubercu-
losis (MDR-TB) and extensively drug-resistant tuberculosis
(XDR-TB) could limit the globally declining trend in tuber-
culosis (TB) prevalence that has been observed in recent
years. It is estimated that worldwide 20 % of previously
treated TB cases and 3.3 % of new TB cases now have
multidrug-resistant tuberculosis – caused by bacterial
strains resistant to at least isoniazid and rifampicin [1].
Treatment for MDR-TB and XDR-TB currently entails
therapeutic regimens with much lower efficacy and
greater toxicity than those used for drug-susceptible TB.
Successful treatment outcome was only reported for
50 % of MDR-TB patients globally in 2014, compared to
86 % for newly diagnosed drug susceptible disease [1],
and second line agents commonly used are poorly toler-
ated. Current recommendations for treatment of MDR-
TB require at least 20 months of therapy [2], though
mounting evidence indicates that shorter regimens may
perform at least as well [3].
Early treatment of MDR-TB is presumed to be associ-
ated with improved treatment outcomes, yet the evidence
in support of this assumption has not been previously
reviewed. Individuals with a prolonged delay to treatment
are perceived as more likely to have a higher bacillary bur-
den, more extensive lung damage and, as a result, active
TB disease that is harder to treat. With the introduction of
rapid diagnostic tools and reported reductions in time to
identification and treatment of MDR-TB in many settings,
there is interest in determining whether such reductions
are associated downstream with improved MDR-TB treat-
ment outcomes. Moreover some countries are struggling
to keep up with the demand for MDR treatment as they
diagnose more and more cases, creating “waiting lists”
wherein patients have to wait until treatment capacity is
available. Demonstration of an adverse effect upon patient
outcome of such delays would be a potentially useful tool
for strengthened advocacy to promote interventions that
enhance linkage of test results to treatment.
We therefore undertook a systematic review of the
existing evidence on the outcomes of multidrug-resistant
and extensively drug-resistant tuberculosis patients treated
early (≤4 weeks) versus late (>4 weeks) after the diagnosis
of drug resistance. This review contributes to the evidence
base for the generation of an updated World Health
Organization (WHO) guideline for the clinical manage-
ment of MDR-TB and XDR-TB.
Methods
PICOT Question
The full original protocol and PRISMA checklist [4]
(Additional file 1: Table S1) are available in the support-
ing information additional file section. The following
amendments or clarifications were made to the original
protocol: searching Google Scholar in place of Google,
including a limit of publication since 1990, including a
10 % check of sifting by a third reviewer, and allowing a
flexible cut-off during sifting in the definition of the tim-
ing of early versus late treatment.
The research question was framed using PICOT (Popu-
lation, Intervention, Comparison, Outcome and Time)
methodology [5, 6]. The population under consideration
was all patients with multidrug-resistant or extensively
drug-resistant tuberculosis bacteriologically confirmed
by phenotypic methods, or for whom molecular testing
indicating rifampicin resistance was used as a surrogate
for initiation of MDR treatment. The intervention and
comparator of interest were early versus late treatment,
defined respectively as drug treatment initiated within
28 days versus later than 28 days after diagnosis of
MDR-TB. The primary outcomes in this review were
the WHO-defined tuberculosis outcomes as proposed
by Laserson et al. [7]: cure, treatment completion, failure/
relapse, transfer out, abandoned treatment and death.
Treatment success was defined as patients meeting the out-
come definition of cure or treatment completed. Poor out-
comes were defined as patients with the outcome of
failure/relapse, transfer out, abandoned treatment or death.
Secondary outcomes pre-defined in the protocol were not
included in the search terms, but were intended for consid-
eration during data extraction from included papers, and
were defined as adverse reactions from TB drugs (severity,
type, organ class), adherence to treatment, or treatment
interruption due to non-adherence.
Search strategy
A comprehensive search strategy was developed in con-
sultation with WHO technical experts using the PICOT
question as a framework (see Additional file 1). Due to
the relatively low number of total hits in preliminary
searches, only population and intervention terms were
used in the search strategy (Additional file 1: Table S2).
By checking for comparator and outcomes defined a priori
during the manual sift instead of in the search strategy,
the likelihood of missing a potentially relevant paper was
reduced. An example of the search strategy, in this case
as applied in PubMed, is included in Additional file 1:
Table S2.
Electronic health care databases, sources of evidence-
based reviews, guidelines, and grey literature were searched
in accordance with the specifications of each database.
These included PubMed (including MEDLINE), EMBASE,
Cochrane library (includes CENTRAL, CDSR, DARE and
HTA databases), WHO Global Index Medicus (includes
LILACS, WPRIM, IMSEAR, IMEMR, AIM, SciELO and
WHOLIS indexes), WHO portal of clinical trials, OpenSI-
GLE, International Union of Tuberculosis and Lung Dis-
ease conference abstracts (2004–2014) and Google Scholar
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(limited to the first ten pages). The search strategies were
executed on 26th September 2015. The date, human stud-
ies and language inclusion criteria were applied in the man-
ual sifting process instead of through the limits function of
PubMed (and other databases) in order to avoid exclusion
of papers that had not been indexed on these criteria
(Table 1).
Manual sifting
Following removal of duplicates, two-stage screening
against inclusion and exclusion criteria was executed
independently by two reviewers (JN, AM), sifting first by
title and abstract, followed by full-text sifting. A third
reviewer (DM) reviewed any discrepant results and every
tenth reference to adjudicate and check for consistency.
Studies including participants of any age with confirmed
multi-drug resistant or extensively drug-resistant pulmon-
ary tuberculosis were potentially eligible for inclusion. Any
consecutive case series, case control study, cohort study,
randomised controlled trial, systematic review or meta-
analysis that included a comparator group was considered
for inclusion. Included studies were required to report
data on at least one of the primary outcome measures of
interest. Although the original intervention of interest was
defined as presumed adequate treatment initiated ≤28 days
after diagnosis, and a comparator group with treatment
initiated >28 days after diagnosis, the protocol was changed
to allow flexibility in the definition of this cut off for early
versus late treatment. Therefore studies reporting outcomes
for patient groups with different definitions for delay to
treatment initiation were considered for inclusion.
Any systematic review superseded by an updated sys-
tematic review, or narrative reviews not adding new
data or new analysis to the existing evidence base were
excluded. Finally, studies not performed in humans,
written in a language other than those listed in Table 1,
or with fewer than ten participants were excluded.
Sifting was primarily managed within Endnote® X7.4
(Thomson Reuters, California, USA). If a paper was
deemed ineligible for inclusion at the full text sifting
stage, the primary reason for ineligibility was recorded
by the reviewers.
Supplementary review and data extraction
An additional post-hoc review of those articles included
in the full text review was undertaken by one reviewer
(DM) using alternative, less-stringent inclusion criteria.
Specifically, papers were identified which reported on
two or more groups of patients with different times to
MDR treatment initiation. Data on treatment outcome
according to WHO criteria or on intermediate outcomes
such as culture conversion time (though not validated as
surrogates of treatment outcome) were abstracted from
papers included in this post-hoc review.
Results
A total of 1978 citations were retrieved from the initial
search of all databases. Breakdown by database source is
provided in Additional file 1: Table S3. After removal of
duplicates (n = 475) and pre-1990 publications (n = 28),
1475 unique citations remained. 1411 hits were excluded
during title and abstract screening. Sixty-four references
were thus identified for full text review and all were re-
trieved [3, 8–70] (Fig. 1).
On full text review none of the 64 references fulfilled
the per-protocol inclusion criteria. Reasons for exclusion
are indicated in Fig. 1.
The most frequent reason for exclusion was the lack
of a comparator group (91 % of full texts reviewed). Pa-
pers often reported average time to treatment, but did
not disaggregate outcomes by timing of treatment, even
with the more relaxed early versus late definition (not
requiring a 28 day cut-off ). Three narrative reviews were
excluded as no new data were presented in addition to
not meeting other inclusion/exclusion criteria for this
review, two research articles were excluded as there were
no reported outcomes of interest, and one reported on
fewer than ten participants.
Supplementary post-hoc review
Although the full text review failed to deliver any publi-
cations fulfilling the inclusion criteria it was noted that a
number of articles reported less well defined data on
treatment delay (without a 28 day cut-off) related to some
interim outcome measures (smear and culture conversion)
and final treatment outcomes [11, 13, 22, 31, 37, 38, 45,
46, 48, 50, 51, 61, 63, 64, 66, 68].
None of these articles addressed the independent
effect of treatment delay with a meaningful comparator
group - whether not delayed or less delayed - upon
treatment outcomes, whether interim or final.
Whilst outside the designated protocol we proceeded
to abstract these data in case the resulting narrative
Table 1 Summary of non-PICO inclusion criteria
Limit category Specified limit Implementation
Languages English, Japanese, Chinese,
Russian, French, Spanish,
Portuguese, Ukrainian, Lithuanian
Manual sifting
Publication type None n/a
Date of publication 1st January 1990–26th Sept 2015 Manual sifting
Study design Consecutive Case Series, Case
Control Studies, Cohort Studies,
Randomised Controlled Trials,
Systematic Reviews
and Meta-analyses
Manual sifting
Other limits None n/a
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yielded any information of use. These data and narrative
summary are reported in Table 2 and Additional file 1:
supplementary text.
Discussion
Whilst there is an inherent logic in the theory that treat-
ment delay will lead, via more severe disease, to worse
treatment outcomes, we were unable to find any pub-
lished evidence to support this assumption. More pertin-
ently, there were no published data demonstrating an
independent effect upon treatment outcome of earlier
initiation of therapy following MDR diagnosis.
It is unfortunate that such data do not exist, as
evidence highlighting a clear direct benefit upon patient-
centred outcomes could have provided a powerful tool
to advocate for specific interventions to improve linkage
of MDR diagnosis to initiation of treatment, a particular
problem for countries facing growing “waiting lists” of
patients diagnosed with MDR-TB awaiting health system
capacity to deliver treatment, or with considerable loss
to follow up between testing and initiation of treatment.
This systematic review found a lack of data rather than a
lack of effect, therefore it should not be assumed that
there is no benefit of early access to treatment. However,
a recent systematic review evaluating the potential bene-
fit of active case finding upon treatment outcomes for
drug susceptible TB failed to demonstrate any improve-
ment over passive case finding, despite the tendency of
active case finding to find cases earlier and with reduced
disease severity [71].
Regardless, beyond the effect for the individual, earlier
treatment initiation should de facto result in reduced
duration of infectiousness and thus result in reduced
transmission at a community level. Treatment for MDR-
TB should clearly be initiated at the earliest opportunity
after diagnosis.
A major obstacle in this review was the lack of suitable
comparator group, as no studies reported treatment out-
comes for otherwise similar patient groups varying only
the time to treatment. Where outcome data were reported
related to time to treatment, it was often confounded by
simultaneous changes in other elements of healthcare de-
livery, such as programmatic changes related to delivery of
care and altered drug regimens. Therefore, it was impos-
sible to attribute differential outcomes to treatment delay.
The authors believe that further research with time to
treatment as the primary research question should not
be considered a high priority amongst competing de-
mands upon limited resources. However, improved data
collection and reporting of patient outcomes by time to
treatment initiation should be encouraged in studies col-
lecting data on the outcomes of interest in this patient
group. Such data could provide important insight with-
out cost implications.
Even if such data were available, treatment delay when
defined as the interval from MDR diagnosis to treatment
fails to take account of delays in reaching an MDR diag-
nosis, the effect of which might overwhelm any potential
benefit of reduced diagnosis-to-treatment time. Roll-out
of new rapid diagnostics, whether molecular tests such
Fig. 1 Flow chart summarising search results
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Table 2 Supplementary post-hoc review data
Author Journal Year Exposure Outcome Comments
Goble [38] NEJM 1993 Duration of disease Failure: continually positive sputum
cultures after at least three months
of therapy
Duration of disease very long
1-3 yrs 12/44
4-8 yrs 18/44 OR 1.8 (0.6-5.4)
≥9 yrs 17/46 OR 1.6 (0.5-5.0)
Chan [37] AJRCCM 2004 Each additional year
delay before first visit to
site
Initial favourable response: ≥3
negative sputum cultures over ≥3
months
OR 0.93 (0.87-0.995) p=0.03
Median pre-therapy disease duration =
4.2 years; analysis takes no account of
time to MDR therapy, just time to first
visit
Bonilla [66] PLoS ONE 2008 Treatment success Paper mainly about individualisation of
regimens with DST and availability of
2nd line DST within 31 days; no data on
lead-in time from diagnosis and
exclusions from primary analyses limit
interpretation
MDR DST available
within ≤31 days
264/334 (79.0%)
MDR DST available after
> 31 days
108/160 (67.5%)
XDR DST available
within ≤31 days
11/14 (78.6%)
XDR DST available after
> 31 days
7/23 (30.4%)
Dheda [31] Lancet 2010 Treatment outcome Delay to treatment Compared delay to treatment in groups
of survivors and non-survivors and
culture converters and non-converters.
Delay to treatment = time from sputum
acquisition to start of treatment
Survival 78 days [53–107]
Death 57 days [36–67]
p=0·001
Culture conversion 91 days [61–116]
Non-conversion 59 days [43–86]
p=0·001
Heller [45] IJTLD 2010 Median days (95%CI) treatment
delay
Before vs. after comparison following
change from traditional hospital based
management (TM) to community based
(CM).
In multivariate analysis time to smear
conversion was longer for TM group
than for CM group (aHR=1.78, p=0.062),
as was time to culture conversion
(aHR=1.82, p=0.026)
Traditional (n=46) 106.5 (88.6-151.1)
Community (n=48) 84 (78.7-93.3) p=0.002
Median days (95%CI) to smear
conversion
Traditional (n=48) 91 (72.2-119.8)
Community (n=32) 59 (34.9-83.1) p=0.055
Median days (95%CI) to culture
conversion
Traditional (n=53) 119 (106.1-131.9)
Community (n=39) 85 (68.0-102.0)
p=0.002
Active and on treatment at 6
months
Traditional 91.2%
Community 84.8%
p=0.4
Seddon [64] CID 2012 Treatment delay
(not defined)
Not associated with:
[1] failure to culture convert by
month 2
(26/74, p=0.25)
[2] unfavourable treatment
outcome
(15/103, p=0.36)
[3] death
(8/103, p=0.18)
Median delay 91 days (IQR 51–166)
Data in table 4 – analysis not clear
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Table 2 Supplementary post-hoc review data (Continued)
Van der Walt
[13]
ERJ (Conference
abstract)
2012 Time to treatment Shorter time to treatment in inpatients
but no differences in time to smear or
culture conversionInpatients 76 days
Community 64 days p<0.01
Sputum conversion
Inpatients 54%
Community 52%
Time to conversion (median with
IQR)
Inpatients 105 (64.5-164)
Community 121 (61.0-206.5)
Loveday [46] IJTLD 2012 Median (IQR) treatment delay in
days
Decentralised vs. centralised hospital
care. Shorter delay to treatment but
worse treatment outcomes for
decentralised care, but many other
differences in care beyond treatment
initiation delay.
Decentralised 72 (56–99)
Centralised 93 (71–120)
p<0.001
Unsuccessful treatment outcomes
Decentralised 96/419 (23%)
Centralised 37/441 (8%)
Cox [63] IJTLD 2014 Median (IQR) treatment delay in
days
MDR programme implemented. But
changes other than treatment initiation
delay e.g. change to include
moxifloxacinBefore (2005) 58 (25–91) (n=39)
During (2010) 31 (18–45) (n=183)
Treatment success
Before (2005–7) 85/206 (41%)
During (2010) 86/164 (52%)
Mpagama [48] PLoS ONE 2013 Median (range) time
from MDR diagnosis to
treatment
Outcome No difference in time from MDR
diagnosis to treatment initiation
between intensive phase completers
and deaths.
272 (26–888) Completion of intensive phase n=54
255 (193–317) Died n=4
p=0.8
Chan [50] PLoS ONE 2013 Delay Treatment success in 3 models
Multiple logistic analysis
Change to programme management in
Taiwan
>120 days 133/194 (69%)
≤120 days 328/457 (72%)
>120 vs.≤120 OR 1.2 (0.8-1.7), p=0.4
Adjusted HRs
0.8 (0.6-0.9), p=0.012
0.8 (0.6-1.0), p=0.018
Delay in 390 patients
with second line drug
susceptibility testing
>120 days 74/117 (63%)
≤120 days 170/273 (62%)
>120 vs. ≤120 OR 1.0 (0.6-1.5), p=0.9
aOR 0.6 (0.4-0.9), p=0.01
Helbling [61] Swiss Med Wkly 2014 Time to treatment Treatment success
39/51 (76.5%)
Time to treatment initiation not
associated with treatment success in
logistic regression model (no data
shown)
Median time to initiation was 5.5 weeks
but 10 initiated MDR treatment
immediately
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Table 2 Supplementary post-hoc review data (Continued)
Kipiani [68] CID 2014 Line probe assay
implementation
Delay to MDR treatment Before vs. after analysis of line probe
assay implementation. Groups differed
in many ways – post implementation
group had more HCV co-infection, more
initial inpatient treatment, more likely to
receive kanamycin instead of
capreomycin, higher rates on prior MDR
treatment, resistant to more drugs.
Pre-implementation 83.9 (56–106)
Post-implementation 18.2 (11–24) p<0.01
(Unclear if overall or just for subset
who received first line drugs)
12 wk culture conversion
Pre-implementation 5/68 (7%)
Post-implementation 25/51 (49%)
24 week culture conversion
Pre-implementation 43/68 (63%)
Post-implementation 44/51 (86%)
p=0.01
24 week smear conversion
Pre-implementation 77%
Post-implementation 90%
p=0.05
Li [51] Lancet Global
Health
2015 Programme
implementation
Median [IQR] time to treatment Time to treatment only reported for
32% and 71% of pre- and post-
intervention patients
Before 139 [69–207]
After 14 [10–21]
Still on treatment at 6 months
Before 8% (2/26)
After 80% (137/172)
Loveday [11] IJTLD 2015 Median (IQR) treatment delay in
days
Includes all of Loveday 2012 data plus
data for 7 additional months
Decentralised 72 (54–97) (n=724)
Decentralised 72 (54–97) (n=724)
Centralised 92 (69–120) (n=811)
p<0.001
Treatment success
Decentralised 427/736 (58%)
Centralised 439/813 (54%) p=0.18
Death
Decentralised 133/736 (18.1%)
Centralised 113/813 (13.9%) p=0.21
Otero [22] TMIH 2015 Treatment outcomes Median (IQR) time in days to MDR-
TB treatment
Should be noted that the duration of
treatment prior to switching was
undetermined.
For patients starting on
MDR regimen:
Success 26 (18–41)
Not success 25 (18–30) p=0.6
For patients switching
to MDR regimen:
Success 11.5 (2–35)
Not success 22 (2–48) p=0.1
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as Xpert MTB/RIF or Genotype MTB DR-plus or direct
phenotypic tests such as MODS or the nitrate reductase
assay, is designed to reduce such delays through im-
proved access and faster laboratory turnaround. Data
comprehensively demonstrating an effect upon outcome
of shortened time to MDR diagnosis are still awaited.
Conclusion
There is currently no published evidence available to as-
sess the effect of early versus late treatment initiation upon
the outcomes of patients treated for MDR-TB or XDR-TB.
Whilst supportive evidence would have provided a useful
advocacy tool, we feel that the intuitive logic and inherent
biological plausibility mean that MDR treatment should
be initiated promptly. Initiating primary research for this
research question is not considered a priority amongst
competing demands upon limited resources. However, im-
proved collection of data on time to treatment initiation
and treatment outcomes within other studies could pro-
vide insight into this question.
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